Our office is located at 5170 Sepulveda Blvd., Suite 210, Sherman Oaks, CA 91403. We accept select PPO insurance plans. For appointments and telehealth consultations, contact us.
1-818-812-7222 Office Hours: Monday Thru Friday: By Appointment only
5170 Sepulveda Blvd. Suite 210
Sherman Oaks, California 91403

Category: Uncategorized

Bowel Function After Duodenal Switch

January 03, 2012 11:34 am

The main questions pre-op patients usually have about Duodenal Switch (D.S.) revolve around bowel function. These are the questions our expert surgeons will address:   Do DS patients have chronic diarrhea? NO Do DS patients spend all day on the toilet? NO Do DS patients have control over their bowels? YES Do DS patients have to wear diapers for the rest of their lives!? NO These are probably the most outrageous pieces of misinformation that is being promoted by those who do not offer D.S. as an alternative to their patients, and patients who wish to justify their reasons for choosing alternative procedures. There will always be patients on either end of the spectrum; some will have a lot more bowel movements than the average post-op patient and some will have far fewer or be constipated. These extreme issues are very rare and are dealt with by the surgeon or other medical specialists. Almost all cases lose frequent bowel function that can be traced back to a patients’ dietary intake. One of the most common contributing factors is excessive fat intake. There is the misconception that since D.S. limits fat absorption, then excessive amounts of fat can be tolerated and some also suggest that it is needed. Both of these may be incorrect; not only does this contribute to excessive loose bowel movements, but it also contributes to the associated loss of nutrients and minerals, such as potassium, vitamin D and serious hydration issues. This is just not the case for the majority of patients. Most D.S. post-op patients have 2-3 bowel movements per day. What the experts say… Baltasar et al., “Gastric emptying in patients with morbid obesity treated with a duodenal switch”, May 1997. [36]
81.3% of Duodenal Switch patients experience normal gastric emptying.
Gary Anthone, MD, “The duodenal switch operation for morbid obesity”, Aug 2005. [9]
The average number of bowel movements per day for 43 pre-op patients was 1.9, 421 patients six months post-op was 2.7, 316 patients twelve months post-op was 2.6 and 113 patients > thirty six months post-op was 2.8.
Wasserberg et al., “Bowel habits after gastric bypass versus the duodenal switch operation.”, Dec 2008. [19]
Although duodenal switch is associated with more bowel episodes than other weight loss procedures, the difference is not statistically significant. Bowel habits are similar in patients who achieve 50% estimated body weight loss with duodenal switch surgery or gastric bypass.
Marceau et al., “Duodenal Switch: Long-Term Results”, Nov 2007, p 1428. [2]
There are negative side effects with DS that is worth mentioning. The unpleasant odor of stool and is always exacerbated by patients’ dietary choices. Artificial sweeteners, carbonated drinks, carbohydrate intake (simple and complex) can all cause or worsen the flatulence after the DS.

Why am I hungry? A look at how hormones regulate our appetite?

November 17, 2011 9:21 pm

One of the main reasons why humans become hungry is because of the hormone ghrelin. Ghrelin is primarily secreted by the stomach, which responds to hunger and starvation. Once ghrelin gets into the blood, it circulates the body until it reaches the Vagus nerve, which sends a signal to your brain that tells you “I am hungry!” Actually, for people who have had their Vagus nerve divided (a Vagotomy), ghrelin no longer has a significant impact on hunger. This finding suggests that the Vagus nerve and ghrelin are needed for maximum stimulation of hunger. Also, ghrelin containing neurons are found in the arcuate nucleus, a region of the brain that regulates appetite. In order to stimulate hunger, these neurons send signals to other neurons that contain neuropeptide Y (NPY), which stimulates hunger. However, if the body wants to suppress hunger, it will send signals to neurons containing proopiomelanocortin (POMC). (i)

Now that we know a little about how ghrelin makes us hungry, lets see how the hormone leptin makes us full. Leptin is made in the fat cells (adipose tissue) of our body. The way leptin regulates hunger is by stimulating or not stimulating nerves in the brain. Just like ghrelin, leptin acts on the arcuate nucleus. When leptin is not present, NPY causes us to be hungry. When leptin levels are high, they block NPY and stimulate POMC nerves in the brain that make us full. However, one might ask, if we have more fat cells that produce leptin, why are we still hungry? The answer is that many obese individuals have genetic defects that block the function of leptin. The other is that too much leptin can cause negative feedback to fat cells, which tell the body “hey we have too much leptin, stop making it.” (ii)

Although the exact mechanisms of how ghrelin and leptin work are extremely complex, we see that the three main responses that are contributed to the presence of ghrelin (iii) (iv) are:

  1. Stimulation of appetite
  2. Reduction of metabolism
  3. Reduction of fat catabolism (fat breakdown)

In contrast to ghrelin, leptin’s main responses are:

  1. Suppression of appetite
  2. Increase in metabolism
  3. Increase immune function

The following table summarizes the information on ghrelin and leptin, its relationship with other GI hormones, and its levels after Sleeve Gastrectomy. (v)

 
Hormone Source Mechanism of action in Obesity Effect on Weight regulation Levels after Sleeve Gastrectomy
Ghrelin Stomach Fundus (mainly), Pancreas, small intestine (vi) Stimulates Growth Hormone release, stimulate NPY, inhibits POMC, and opposes Leptin action Stimulates Appetite, Reduces metabolic rate, and reduces fat catabolism (breakdown) Reduced
PYY (peptide tyrosin tyrosine) Is released by endocrine cells of distal ileum, colon, and rectum(vii) Binds to NPY receptors, inhibits gastric motility, increases water and electrolyte absorption in the colon (vii) Reduced appetite Increased
Leptin Fat cells (adipose tissue) Inhibit NPY and activates POMC Suppress Appetite Reduced

By: Chris Tashjian BS – Ara Keshishian MD, FACS, FASMBS

(i) Sato T, Nakamura Y, et al. Structure, regulation, and function of Ghrelin. Journal of Biochemistry. Oct 31, 2011.

(ii) Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998 Oct 22; 395 (6704): 763-70

(iii) Le Roux CW, Aylwin SJ, Batterham RL, et al. Gut Hormone profiles following baraitric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006; 243:108-114.

(iv) Hansen TK, Dall R, Hosoda H. et al. Weight loss increases circulating levels of ghrelin in human obesity. Clin. Endocrinology 2002; 56:203-206

(v) Melissa Gianos, et al. Understanding The Mechanisms of Action of Sleeve Gastrectomy on Obesity. Bariatric Times 8;5: S4-S6 (Supplement)

(vi) Ariyasu H, Takaya K et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endrocrinology Metabolism. 20001;86:4753-4758

(vii) Liu CD, Aloia T, et al. Peptide YY: a potential proabsorptive hormone for the treatment of malabsorptive disorders. American Journal of Surgery. 1996 Mar; 62(3) 232-6.

Is my weight loss surgery reversible?

May 23, 2011 2:39 am

“The LAP-BAND® System is reversible and, if necessary, can be removed — with the stomach usually returning to its original shape.”

This is a direct quotation from the manufacture’s website. It is a statement of its reversible state that is usually used to promote the adjustable gastric banding procedure compared to other surgical alternatives. In my practice I am a very strong advocate of the Duodenal Switch operation and as a distant second, I offer Sleeve Gastrectomy. I do not offer or recommend the Gastric Bypass (RNY, proximal or distal) procedures because of their well known complications of dumping syndrome, weight regain, inadequate weight loss, as well as anatomical complication of stricture or marginal ulcerations that are seen.

I would only assume that the reversibility issue is to be discussed if the procedure is expected to fail frequently . As a surgeon who performs the duodenal switch operation as a primary weight loss surgical procedure, I have rarely had to reverse the procedure. In my opinion, the physiologic reversal of the duodenal switch operation is by far the easiest of all surgical procedures. It involves creation of a side-to-side anastomosis between the alimentary and the biliopancreatic limbs.

The following are images of a Lap-Band® being removed because the patient kept suffering from persistent nausea and vomiting. The operation was performed laparoscopically. The operative finding identified a significant amount of reactive tissue (scar formation) that represented substantial difficulty in the operating room from a technical point of view. The long term damage done to organs by the Lap-Band makes it not easily reversible.

My recommendations for any individual considering a weight loss surgery is not to focus on the ease of reversibility of the procedure, but rather its long-term outcome data as the basis for choosing an operation.

Psychiatric Medications and Weight Gain

April 07, 2011 9:11 pm

One of the most common and frequent questions asked by patients is the relationship between psychiatric medications and their effect on weight loss after surgery. This is a summary of an article that was published in March 2011 issue of Bariatric Times magazine. The incidence of major depressive disorder is between 2-9% in general population. The World Health Organization reports increasing incidence of depression and other psychiatric illnesses.

There is a complex relationship that exists between depression and obesity. This relationship is even more complicated when one considers the sex of the patient. An example is that men with obesity are less likely to suffer from depressive disorders than normal weight men. Underweight men however are more likely to suffer from depressive disorders and suicidal ideation. This data comes from a study that included 40,000 individuals.

There are a number of different classes of psychiatric medications. These include tricyclic antidepressants (TCA), the newer selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI) and dopamine and norepinephrine reuptake inhibitors (DNRI). And then there are a few, such as Wellbutrin, that do not belong to any of those groups noted.

In general weight gain is more common with TCA medications. There are some in which some weight loss is also noted. The table below outlines a summary of weight neutrality, relative weight gain or weight loss for a number medication. The mechanism by which the weight gain or weight loss occurs is not clear for all medications.

The relationship between antidepressants, mood stabilizers, antipsychotic and weight gain is an example of how important it is for all health care providers to be aware off a patient’s medications and it’s possible side effect on weight gain.

 
Medication Effect on Weight
Antidepressants
Elavil Gain
Wellbutrin Loss
Celexa Neutral
Pristiq Neutral
Cymbalta Neutral
Prozac Loss
Luvox Neutral
Paxil Gain
Zoloft Mild Gain
Effexor Possible Gain / Neutral
Antipsychotics
Abilify Neutral
Thorazine Neutral
Clozaril Significant Gain
Haldol Neutral
Zypreza Significant Gain
Seroquil Gain
Risperidal Gain
Geodon Significant Gain
Mood Stablizer
Lamictal Neutral
Lithium Gain
Topomax Loss
Depakote Significant Gain

Note: Individual results may vary and this is not meant to be an inclusive list of medications

The truth about gastric bypass is out!

January 21, 2011 12:28 pm

By Charles Bankhead, Staff Writer, MedPage Today
Published: June 26, 2009
Reviewed by Zalman S. Agus, MD; Emeritus Professor University of Pennsylvania School of Medicine and Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner

DALLAS, June 26 — Patients who undergo gastric bypass surgery often have undiagnosed glucose abnormalities that can lead to bad eating habits and regained weight, a small clinical study suggests.

Almost 80% of the patients had glucose abnormalities, including hyperglycemia, hypoglycemia, or both, Mitchell Roslin, MD, of Lenox Hill Hospital in New York, reported here at the American Society of Metabolic and Bariatric Surgery meeting. Patients were alarmed by the weight regain, but at the same time, they often had a ravenous appetite soon after a meal, accompanied by an almost uncontrollable urge to eat.” Our hypothesis is that . . . patients may have an enhanced insulin response,” said Dr. Roslin. “They have rapid emptying of the pouch that leads to reactive hypoglycemia. The combination of an empty pouch and low blood sugar leads to hunger.” The findings have led him to question whether gastric bypass surgery should remain the gold standard procedure for treating obesity, he added. At the very least, surgeons should consider the possible need to include a valve in gastric bypass.

The study evolved from clinical observations during patients’ periodic postoperative visits. A growing number of patients complained of weight regain and loss of restriction. The complaints often had a common ring.” Patients were saying that one or two hours after eating, they were ravenously hungry,” said Dr. Roslin. “It sounded a lot like hypoglycemia to me.” To investigate the origin of the symptoms, Dr. Roslin and colleagues studied 63 patients who had undergone gastric bypass procedures. All the patients had a 100-g glucose tolerance test, wherein the maximum/minimum glucose ratio was assessed one to two hours after the glucose challenge.The investigators defined reactive hypoglycemia as a glucose value <60 mg/ dL, or a decrease of 100 mg/dL or more within two hours and no glucose value exceeding 200 mg/dL. They defined hyperglycemia as any value >200 mg/dL and no value <80 mg/dL. Follow-up from surgery averaged about four years. The mean age of the group was 48.5, and 81% were women. The patients’ average preoperative weight was 138 kg, with an average body mass index of 49. One-third had preoperative diabetes. The percentage of excess BMI lost averaged 55%, and the patients had regained an average of 12 kg. Glucose tolerance tests showed six patients with hyperglycemia, including five who had normal fasting blood glucose levels. In addition, 35 patients had reactive hypoglycemia, while eight had hyper- and hypoglycemia. “The hyperglycemic cohort was characterized by a rapid rise to high sugar levels,” said Dr. Roslin. “The fact that most of these patients had normal fasting glucose means we need to be very careful of what we call cure or control of diabetes.” Reactive hypoglycemia manifested as a rapid upsurge of glucose levels that correlated with a rise in insulin and then a rapid decline during the second hour after the glucose challenge. Patients with both hyper- and hypoglycemia had even more pronounced swings in glucose and insulin levels, said Dr. Roslin.

The most dramatic rises and falls in blood glucose have been associated with small pouches and wide anastomoses, he added. The findings suggest a need to consider alterations in the standard gastric bypass procedure, such as use of valves, or possibly abandonment of the procedure in favor of another approach. “I believe that vertical-sleeve gastrectomy and duodenal switches that are not severely malabsorptive will be the best options in the future,” said Dr. Roslin.

Editorial: The about article was sent to me by Vicki Blackburn- Thank you Vicki. This was one of the many presentations that was made at the ASMBS meeting held in Dallas. I will be sharing other presentation in the future newsletters. This article describes what those if us that have been preforming duodenal switch operation have knows for years. This explains why the size of the pouch does not matter, that dumping does not protect against weight gain and why duodenal switch operation is far better option that the alternatives. As with other procedures the science will eventually shed light on all the facts. Dr. Roslin indicates the time is now to consider what should be the benchmark standard for weight loss.
Ara Keshishian MD, FACS

Vitamin A

January 01, 2011 1:42 pm

Benefits of Vitamin A

– It is crucial for the proper utilization of protein. – It is stored in the liver and it helps purify the bloodstream. – It helps maintain healthy skin and is used in the treatment of acne. – It prevents night blindness and is prescribed for eye disorders. – It protects the body from bacterial and viral infections. – It keeps skin and tissues healthy. – It is thought to be of value in retarding cancer growth. – It helps to maintain healthy thyroid balance.

Best Absorbed Form

Retinol; retinyl palmitate and retinyl acetate.

Take With

B complex, vitamin D, vitamin E, calcium and zinc (since zinc gets vitamin A out of its storage deposits)

Don’t Take With

Iron, copper, phosphorus, magnesium or calcium When zinc is combined with certain foods it may not be absorbed into your body. Avoid the following foods for approx 2 hours after you take zinc: bran, fiber-containing foods, whole-grain breads and cereals, and phosphorus-containing foods such as milk or poultry.

Information on Vitamin A

Two of the most common vit A sources are retinol and beta-carotene. Retinol is sometimes called “true” vit A because it is nearly ready for the body to use. Principle forms of retinol in supplements are retinyl palmitate and retinyl acetate. Beta-carotene is a precursor for vit A. The body needs to convert it to retinol for use so as a result it is preferable to supplement with retinol sources. According to the AACE/TOS/ASMBS Guidelines [55] for post-op Duodenal Switch patients with deficiency symptoms, aggressive oral supplementation, up to 65,000 IU/day of vitamin A, can normalize dark adaptation and the serum vitamin A level after 2-3 months. Check with your surgeon for the suggested post-op daily supplementation.

For more information on Vitamin A

Vitamin A: The Vitamin That Helps Reduce Sun-Related Skin Damage 

Zinc

January 01, 2011 1:39 pm

Benefits of Zinc

– Plays a role in immune function, protein synthesis, wound healing, DNA synthesis, and cell division. – Plays an important role in the immune system, which may explain why it is helpful in protecting against infections such as colds. – Plays a role in the regulation of appetite, stress level, taste, and smell. – It is essential for normal growth and development.

Best Absorbed Form

Chelated zinc gluconate

Take With

Take with food if needed, zinc can be hard on your stomach.

Don’t Take With

Iron, copper, phosphorus, magnesium or calcium When zinc is combined with certain foods it may not be absorbed into your body. Avoid the following foods for approx 2 hours after you take zinc: bran, fiber-containing foods, whole-grain breads and cereals, and phosphorus-containing foods such as milk or poultry.

Information on Zinc

Zinc is an essential trace mineral, which means that it must be obtained from the diet since the body cannot make enough. A daily intake of zinc is required because the body doesn’t have a zinc storage system. Zinc is eliminated in stool and is dependent on fat for absorption. [55] As a result it can be assumed that due to the larger and more frequent stools following DS increase zinc loss, and thus increase supplement requirements. [66] Research has shown that less than 50 mg a day is a safe amount to take over time. There has not been a lot documented on what happens if more is taken over a long period. Taking more than 150 mg per day may interfere with the body’s ability to use other minerals. [67]

Relationship Between Zinc and Copper

A strong relationship exists between zinc and copper. Too much of one can cause a deficiency in the other. Long-term use of zinc (including zinc in a multivitamin) should be accompanied by copper. For every 15 mg of zinc, include 1 mg of copper. [67] High doses of zinc may lower HDL (“good”) cholesterol and raise LDL (“bad”) cholesterol. This may be due to a copper deficiency brought on by the long-term use of zinc. [67] Copper is also needed to help your body use iron.

For More Information on Zinc

www.drugs.com University of Maryland Medical Center  National Institute of Health 

Probiotic

November 12, 2010 7:58 pm

The term “probiotic” is getting much attention in professional circles as well as in the advertising media but is still poorly understood by many. The term describes beneficial bacteria that are added to our diet to help populate our digestive system with a healthy population of good bacteria. It is becoming ever clearer that a healthy population of bacteria is very important for our overall health. Our gut is the most intimate contact between the interior of our body and the outside world much as our skin is. The gut must remain permeable to nutrients which we absorb from foods yet impermeable to invading bacteria and viruses. The bacterial population of our gut plays important roles in both of those functions. It is also very important in the function of our overall immune function. I will leave that for another time. The purpose today is to discus the use and function of probiotic products.

The human gut is populated by tens of billions of bacteria of a yet to be discovered number of species. In excess of six hundred have already been isolated and identified. Some of these species are beneficial, some are harmful and some are a bit of both. Unfortunately modern society tends to have a negative impact on the health and balance of the members of the probiotic population. Chlorinated water, antibiotics both as medications and in our food and even our food choices can cause an imbalance in this population. When this balance is severely disrupted it is termed “Disbiosis”. A disbiotic gut is not a happy thing. We perceive this disbiosis as digestive symptoms of some sort. We may have gas and bloating, constipation or diarrhea, or even both or all of the above. One of the unfortunate aftereffects of having bariatric (weight loss) surgery is it can allow the gut to become disbiotic more easily.

In the DS gut food reaches the large intestine far more nutrient rich than in the “normal” gut. This provides the population of bacteria living there much more food. Given more food the population can flourish. If this population is out of balance it is even more sensitive to poor food choices thereby making the symptoms of this imbalance even worse. This is why the DS patient needs to make prudent food choices and may well enjoy great benefit from proper doses of high quality probiotic products containing the correct species.

The problem is that not all probiotic products are what they say they are and not all probiotic products have the same species. Add to that the fact that each gut is individual. We may need to do some experimentation to find the right combination of dose and product.

Some people have what I term a McDonald’s mentality. A Big Mac in one town is exactly the same as one from a different town or, as another example, a gallon of Shell unleaded gasoline is essentially the same as a gallon of gas from the Chevron station. This is not the case with probiotic products. Some products contain only one species and some contain thirteen or more. These various species, with one exception fall, into two large groups these are Lactobacillus species which predominate in the small intestine and Bifidobacterium species which predominate in the large intestine. The one exception is actually not a bacterium at all but rather a specific yeast. This yeast is very important and beneficial. It is called Saccharomyces boulardii. Some patients have reported good results with single species products such as Align (B. infantus), Culturelle (L. rhamnosus) or Floristor (S. boulardii). My feeling is that these products are overly expensive as they are heavily advertised and that cost is built into the price. They also tend to be rather low dose.

We also need to address the correct dosage. It is important to read the label. Minimum “therapeutic” dosage is thought to be 20 billion colony forming units (CFU’s). I personally am using 50 billion CFU’s per day as maintenance. I have taken as much as 200b CFU’s per day. I am also aware of research going on that also is looking at similarly high dosage.

I think a good product to start with is “Primal Defense Ultra”. Make sure it is the “Ultra” as it is the stronger blend. It is reasonably priced and contains a total of 13 species including the very important S. boulardii. For DS patients experiencing a disbiosis creating very foul flatus and stool. This species as an ingredient is very important. The S. boulardii has very specific activity against some of the nastiest bad guys in our gut such as Clostridium difficile, Candida albicans and even Entameba histolytica and Giardia lamblia which have been shown to enhance the effectiveness of conventional therapy for these conditions. In less severe cases the probiotics alone may be sufficient to correct the disbiosis but more severe cases antibiotic therapy may be indicated.

As stated previously the dosage needs to be sufficient. Three caps per day of Primal Defense Ultra (PDU) is a commonly used dose. This provides a total of 45b CFU’s with 12b of that total as S. boulardii. This was the dose used in a recent case study looking at DS patients with recurring frank C.diff treated with antibiotic and S. boulardii. Statistically very significant benefit was shown.

Also as stated previously every gut is different. Some may do well on small doses and some may need more. Every patient needs to find the dose that works for them. We need to start slowly and work up. Some increase in gas and bloating may occur. Once the disbiosis is improved patients can experiment with different blends. It is suggested that there be several species of both the lacto and bifido groups. The only allergic reaction I have heard of is one patient who developed a slight rash which subsided after lowering the dose. You can find this is most health food stores but it is a much better deal on line. Typically about 90 caps for $37 vs. 218 caps for about $50. General rule of thumb is that the refrigerated brands are superior to the less expensive freeze dried ones. But, many do well with the less expensive brands. Again, you need to experiment.

Also as stated prudent food choices are extremely important. Things like lean protein, complex carbohydrates and whole grains. Avoidance artificial sweeteners and simple sugars and white flour are all prudent decisions.

 

By: David Caya, DC

Duodenal Switch for Super Morbid Obesity

November 06, 2010 1:43 pm

Clinical data addressing Duodenal Switch for super morbid obesity (BMI > 50). Outcome of laparoscopic duodenal switch for morbid obesity.  Magee et al. Oct 2010 PubMed Abstract BACKGROUND: The aim of this study was to determine the safety and efficacy of laparoscopic duodenal switch (LDS) as a treatment option in a selected group of patients with morbid obesity. METHODS: This retrospective analysis of a prospective database assessed the frequency of all complications and alterations in weight, body mass index (BMI), co-morbidity and quality of life. RESULTS: One hundred and twenty-one patients underwent LDS between April 2003 and March 2009. Median preoperative weight was 160 kg and median BMI 55 kg/m2. All procedures were performed laparoscopically. The in-hospital mortality rate was zero. No ileoduodenal anastomotic stenosis was encountered. There were four clinical leaks (3.3 per cent) managed by laparoscopic drainage and placement of a feeding jejunostomy. Median percentage excess weight loss was 75 per cent at 12 months and 90 per cent at 24 months. Thirty-six of 40 diabetic patients had complete resolution of diabetes within 1 year. There were significant improvements in other obesity-related co-morbidity. Only a few patients developed postoperative protein deficiency, and fat-soluble vitamin deficiencies were easily managed with oral supplementation. CONCLUSION: The LDS procedure is a safe and effective treatment for morbid obesity and its associated co-morbidity in selected patients. Copyright © 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. Randomized clinical trial of laparoscopic gastric bypass versus laparoscopic duodenal switch for superobesity.  Søvik et al. Feb 2010 PubMed Abstract  BACKGROUND: Laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic biliopancreatic diversion with duodenal switch (LDS) are surgical options for superobesity. A randomized trial was conducted to evaluate perioperative (30-day) safety and 1-year results. METHODS: Sixty patients with a body mass index (BMI) of 50-60 kg/m(2) were randomized to LRYGB or LDS. BMI, percentage of excess BMI lost, complications and readmissions were compared between groups. RESULTS: Patient characteristics were similar in the two groups. Mean operating time was 91 min for LRYGB and 206 min for LDS (P < 0.001). One LDS was converted to open surgery. Early complications occurred in four patients undergoing LRYGB and seven having LDS (P = 0.327), with no deaths. Median stay was 2 days after LRYGB and 4 days after LDS (P < 0.001). Four and nine patients respectively had late complications (P = 0.121). Mean BMI at 1 year decreased from 54.8 to 38.5 kg/m(2) after LRYGB and from 55.2 to 32.5 kg/m(2) after LDS; percentage of excess BMI lost was greater after LDS (74.8 versus 54.4 per cent; P < 0.001). CONCLUSION: LRYGB and LDS can be performed with comparable perioperative safety in superobese patients. LDS provides greater weight loss in the first year. Registration number: NCT00327912 (https://www.clinicaltrials.gov). Copyright (c) 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. Duodenal switch provides superior resolution of metabolic comorbidities independent of weight loss in the super-obese (BMI > or = 50 kg/m2) compared with gastric bypass.  Prachand et al. Feb 2010 PubMed Abstract  OBJECTIVE: Increased body mass index is associated with greater incidence and severity of obesity-related comorbidities and inadequate postbariatric surgery weight loss. Accordingly, comorbidity resolution is an important measure of surgical outcome in super-obese individuals. We previously reported superior weight loss in super-obese patients following duodenal switch (DS) compared to Roux-en-Y gastric bypass (RYGB) in a large single institution series. We now report follow-up comparison of comorbidity resolution and correlation with weight loss. METHODS: Data from patients undergoing DS and RYGB between August 2002 and October 2005 were prospectively collected and used to identify super-obese patients with diabetes, hypertension, dyslipidemia, and gastroesophageal reflux disease (GERD). Ali-Wolfe scoring was used to describe comorbidity severity. Chi-square analysis was used to compare resolution and two-sample t tests used to compare weight loss between patients whose comorbidities resolved and persisted. RESULTS: Three hundred fifty super-obese patients [DS (n=198), RYGB (n=152)] were identified. Incidence and severity of hypertension, dyslipidemia, and GERD was comparable in both groups while diabetes was less common but more severe in the DS group (24.2% vs. 35.5%, Ali-Wolfe 3.27 vs. 2.94, p<0.05). Diabetes, hypertension, and dyslipidemia resolution was greater at 36 months for DS (diabetes, 100% vs. 60%; hypertension, 68.0% vs. 38.6%; dyslipidemia, 72% vs. 26.3%), while GERD resolution was greater for RYGB (76.9% vs. 48.57%; p<0.05). There were no differences in weight loss between comorbidity “resolvers” and “persisters”. CONCLUSIONS: In comparison to RYGB, DS provides superior resolution of diabetes, hypertension, and dyslipidemia in the super-obese independent of weight loss. Duodenal Switch Operative Mortality and Morbidity Are Not Impacted by Body Mass Index.  Buchwald et al. Oct 2008 PubMed Abstract  OBJECTIVE: This report examines the up to 30-day postoperative mortality and morbidity in our first 190 duodenal switch (DS) patients. BACKGROUND DATA: DS is the most weight loss effective and the most difficult to perform bariatric procedure. Indeed, certain surgeons have advocated a 2-stage approach to minimize complications, especially in the super obese (body mass index [BMI] >/=50 kg/m). METHODS: DS procedures were performed (n = 190) by either open (n = 168) or laparoscopic/robotic surgery in an academic setting: common channel 75 to 125 cm, sleeve gastrectomy (approximately 100 mL gastric pouch), closed duodenal stump, end-to-side duodenoileostomy hand-sewn in 2 layers, with most staple lines oversewn, and all mesentery defects closed. RESULTS: For the 190 patients, 149 were female (78%) and the mean age was 43 years (range, 16-71). Mean preoperative weight 151.4 kg (range, 74.1-332.7); mean preoperative BMI 53.4 kg/m (range, 32-107), with 100 (52.6%) of the patients super obese (BMI >/=50 kg/m). Seventy-four patients had concurrent procedures, eg, cholecystectomy (n = 22), ventral or umbilical hernia repair (n = 19), and hiatus hernia repair (n = 10). Mean operating room time was 337 minutes (range, 127-771); mean hospitalization time was 6 days (range, 2-38). There were no deaths. Serious /=50 kg/m (NS). Surgical site infections occurred in 7 patients with a BMI <50 kg/m and in 12 with a BMI >/=50 kg/m (NS). Overall complication rate in patients with a BMI <50 kg/m was 14.4% (13 of 90) and 24% (24 of 100) with a BMI >/=50 kg/m (NS). CONCLUSIONS: With attention to careful surgical technique, DS can be performed relatively safely in the morbidly and super morbidly obese, and does not require a 2-stage procedure. Outcome of duodenal switch with a transitory vertical gastroplasty, in super-super-obese patients in an 8-year series.  Di Betta et al. Feb 2008 PubMed Abstract  BACKGROUND: In super-super obese (SSO) patients [body mass index (BMI) superior of 60 kg/m2] results of bariatric surgery are still controversial. This study evaluated safety and efficacy of open duodenal switch associated with transitory vertical gastroplasty (DS-TVG) after 8 years of follow-up. METHODS: A prospective observational study of 32 SSO patients who underwent an open DS-TVG from January 1999 till March 2006 was performed. Study endpoints included preoperative comorbidities [diabetes, hypertension, and obstructive sleep apnea syndrome (OSAS)], postoperative morbidity and mortality, and long-term results of BMI and percent of excess weight loss (%EWL) (median 48 months). RESULTS: Results in terms of BMI and %EWL were, respectively, after 12 months, 46.3 +/- 10.2 and 57.1 +/- 9.8; after 36 months (n = 21), 37.5 +/- 7.5 and 73.5 +/- 6.2; and after 84 months (n = 5), 31.7 +/- 2.8 and 76.0 +/- 4.1. With regard to comorbidities, we observed complete control of lipid alterations and type-2 diabetes (suspension therapy within 1 year). All patients with OSAS improved within 1 year without needing domiciliary oxygen therapy. Neither malnutrition nor mortality was observed during the follow-up. Major complications occurred in a total of 5 patients (15.6%): pulmonary embolism (2 cases-9.4%); gastrointestinal bleeding, requiring transfusions (1 case-3.1%); 1 case (3.1%) of abdominal rupture; and 1 case of acute pancreatitis (3.1%). Minor complications occurred in 4 patients (12.5%): 1 case of pneumonia, 1 urinary tract infection, and 2 wound infections. CONCLUSION: Although this study evaluated the outcomes of a small series of patients after open DS-TVG, this procedure seems to be safe and effective in obese patients who have a BMI greater than 60 kg/m2. In our opinion, DS-TVG should be considered as a valid surgical option with two staged laparoscopic procedures. Duodenal Switch Provides Superior Weight Loss in the Super-Obese (BMI >50kg/m2) Compared With Gastric Bypass  Prachand et al. Oct 2006 PubMed Abstract  Full Article  OBJECTIVES: Although weight loss following Roux-en-Y gastric bypass is acceptable in patients with preoperative body mass index (BMI) between 35 and 50 kg/m, results from several series demonstrate that failure rates approach 40% when BMI is > or =50 kg/m. Here we report the first large single institution series directly comparing weight-loss outcomes in super-obese patients following biliopancreatic diversion with duodenal switch (DS) and Roux-en-Y Gastric Bypass (RYGB). METHODS: All super-obese patients (BMI > or =50 kg/m) undergoing standardized laparoscopic and open DS and RYGB between August 2002 and October 2005 were identified from a prospective database. Two-sample t tests were used to compare weight loss, decrease in BMI, and percentage of excess body weight loss (% EBWL) after surgery. chi analysis was used to determine the rate of successful weight loss, defined as achieving at least 50% loss of excess body weight. RESULTS: A total of 350 super-obese patients underwent DS (n = 198) or RYGB (n = 152) with equal 30-day mortality (DS,1 of 198; RYGB, 0 of 152; P = not significant). The % EBWL at follow-up was greater for DS than RY (12 months, 64.1% vs. 55.9%; 18 months, 71. 9% vs. 62.8%; 24 months, 71.6% vs. 60.1%; 36 months, 68.9% vs. 54.9%; P < 0.05). Total weight loss and decrease in BMI were also statistically greater for the DS (data not shown). Importantly, the likelihood of successful weight loss (EBWL >50%) was significantly greater in patients following DS (12 months, 83.9% vs. 70.4%; 18 months, 90.3% vs. 75.9%; 36 months, 84.2% vs. 59.3%; P < 0.05). CONCLUSIONS: Direct comparison of DS to RYGB demonstrates superior weight loss outcomes for DS.

Laparoscopic Duodenal Switch

November 06, 2010 12:43 pm

Studies on the laparoscopic Duodenal Switch procedure. Outcome of laparoscopic duodenal switch for morbid obesity.  Magee et al. Oct 2010 PubMed Abstract BACKGROUND: The aim of this study was to determine the safety and efficacy of laparoscopic duodenal switch (LDS) as a treatment option in a selected group of patients with morbid obesity. METHODS: This retrospective analysis of a prospective database assessed the frequency of all complications and alterations in weight, body mass index (BMI), co-morbidity and quality of life. RESULTS: One hundred and twenty-one patients underwent LDS between April 2003 and March 2009. Median preoperative weight was 160 kg and median BMI 55 kg/m2. All procedures were performed laparoscopically. The in-hospital mortality rate was zero. No ileoduodenal anastomotic stenosis was encountered. There were four clinical leaks (3.3 per cent) managed by laparoscopic drainage and placement of a feeding jejunostomy. Median percentage excess weight loss was 75 per cent at 12 months and 90 per cent at 24 months. Thirty-six of 40 diabetic patients had complete resolution of diabetes within 1 year. There were significant improvements in other obesity-related co-morbidity. Only a few patients developed postoperative protein deficiency, and fat-soluble vitamin deficiencies were easily managed with oral supplementation. CONCLUSION: The LDS procedure is a safe and effective treatment for morbid obesity and its associated co-morbidity in selected patients. Copyright © 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. Clinical application of laparoscopic bariatric surgery: an evidence-based review.  Farrell et al. May 2009 PubMed Abstract  BACKGROUND: Approximately one-third of U.S. adults are obese. Current evidence suggests that surgical therapies offer the morbidly obese the best hope for substantial and sustainable weight loss, with a resultant reduction in morbidity and mortality. Minimally invasive methods have altered the demand for bariatric procedures. However, no evidence-based clinical reviews yet exist to guide patients and surgeons in selecting the bariatric operation most applicable to a given situation. METHODS: This evidenced-based review is presented in conjunction with a clinical practice guideline developed by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). References were reviewed by the authors and graded as to the level of evidence. Recommendations were developed and qualified by the level of supporting evidence available at the time of the associated SAGES guideline publication. The guideline also was reviewed and co-endorsed by the American Society for Metabolic and Bariatric Surgery. RESULTS: Bariatric surgery is the most effective treatment for severe obesity, producing durable weight loss, improvement of comorbid conditions, and longer life. Patient selection algorithms should favor individual risk-benefit considerations over traditional anthropometric and demographic limits. Bariatric care should be delivered within credentialed multidisciplinary systems. Roux-en-Y gastric bypass (RGB), adjustable gastric banding (AGB), and biliopancreatic diversion with duodenal switch (BPD + DS) are validated procedures that may be performed laparoscopically. Laparoscopic sleeve gastrectomy (LSG) also is a promising procedure. Comparative data find that procedures with more dramatic clinical benefits carry greater risks, and those offering greater safety and flexibility are associated with less reliable efficacy. CONCLUSIONS: Laparoscopic RGB, AGB, BPD + DS, and primary LSG have been proved effective. Currently, the choice of operation should be driven by patient and surgeon preferences, as well as by considerations regarding the relative importance placed on discrete outcomes. Laparoscopic Technique for Performing Duodenal Switch with Gastric Reduction  Rabkin et al. April 2003 PubMed Abstract  Full Article  BACKGROUND: The duodenal switch procedure with gastric reduction (DS) is a hybrid procedure for morbidobesity that combines moderate intake restriction with moderate malabsorption. This report describes the laparoscopic hand-assisted technique for the duodenal switch procedure (LapDS). METHODS: Restriction is achieved via a greater curvature gastrectomy, reducing gastric capacity to 120ml. The malabsorptive component is constructed by dividing the duodenum 4 cm distal to the pylorus and anastomosing the proximal duodenum to the distal 250 cm of ileum. The biliopancreatic limb is anastomosed to create a 100 cm common channel. Laparoscopic cholecystectomy, cholangiogram, liver biopsy and appendectomy are performed in conjunction with DS. RESULTS: 345 LapDS procedures (27 lap-assisted; 318 hand-assisted) were performed betweenSeptember 1999 and February 2002. There were 299 women and 46 men with a mean age of 43 years(range 19-67 years). Mean BMI was 50 (range 36-118 kg/m2). Mean operating time was 201 minutes (range 105-480). The median length of hospital stay was 3.0 days (range 2-22 days, excluding one outlier). There were 7 conversions to open laparotomy, 14 reoperations, and 21 readmissions. There were 3 pulmonary emboli, 2 deep venous thromboses, and 4 perioperative proximal anastomotic strictures. There were no deaths. Mean percent excess weight loss at 6, 18, and 24 months was 51%, 89%, and 91%, respectively. CONCLUSION: Laparoscopic assisted duodenal switch procedure can be performed safely with acceptable operative times and without excess morbidity or mortality. Early Results of Laparoscopic Biliopancreatic Diversion with Duodenal Switch: A Case Series of 40 Consecutive Patients.  Gagner et al. Dec 2000 PubMed Abstract  Full Article  BACKGROUND: Biliopancreatic diversion with duodenal switch (BPD-DS) is an operation which provides one of the greatest maintained weight losses of any bariatric procedure. We looked at the safety and efficacy of laparoscopic BPD-DS for morbid obesity. METHODS: A 150-200 ml sleeve gastrectomy was created and anastomosed to the distal 250 cm of divided ileum. The median length of the common channel was 100 cm. All patients were prospectively followed up to 12 months. RESULTS: 40 consecutive patients underwent laparoscopic BPD-DS as a primary procedure for morbid obesity. Median patient body mass index (BMI) was 60 kg/m2 (range 42-85 kg/m2). Mean age was 43 +/- 1 years (+/- SEM), with 12 males and 28 females. One patient was converted to open laparotomy (2.5%). Median operative time was 210 +/- 9 minutes (range 110-360 minutes) with a significant correlation between BMI and operative time (p = 0.04). Median length of stay was 4 days (range 3-210 days). There was one 30-day mortality (2.5%). Major morbidities occurred in 6 patients (15%), including 1 anastomotic leak (2.5%), 1 venous thrombosis (2.5%), 4 staple-line hemorrhages (10%) and 1 subphrenic abscess (2.5%). Median follow-up at 6 months (range 1-12 months) resulted in 46% +/- 2% excess weight loss (EWL) and at 9 months 58% +/- 3% EWL. CONCLUSION: Laparoscopic BPD-DS is a complex, yet feasible, procedure resulting in effective weight loss with an acceptable morbidity. A BMI >65 was associated with increased morbidity and mortality. A long-term study is needed to confirm efficacy and proper patient selection.